Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. This growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions rising 36% and refills surging 207%. These numbers underscore the strong market acceptance of TONMYA, which is the first new treatment for fibromyalgia in over 15 years.
The company's commercial progress is further highlighted by TONMYA's coverage, which currently represents approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broad coverage is crucial for patient access and could drive further prescription growth, positioning TONMYA as a major revenue generator for Tonix.
Beyond TONMYA's commercial success, Tonix is advancing its clinical pipeline to address high unmet medical needs. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, a condition that affects millions worldwide. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives demonstrate Tonix's commitment to expanding its portfolio beyond fibromyalgia and addressing critical therapeutic areas.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This solid financial position provides a runway to support ongoing commercial activities and clinical development programs.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. In addition to TONMYA, the company's CNS commercial infrastructure supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also evaluating TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The strong Q2 results and pipeline advancements are pivotal for Tonix as it seeks to establish itself as a leader in CNS and immunology therapeutics. The revenue growth from TONMYA not only validates the commercial execution but also provides the financial foundation to invest in future growth opportunities. As the company continues to expand coverage and progress its clinical programs, stakeholders will be watching closely to see if the momentum can be sustained.
